跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 13,511 条关于
“Jiangsu Tasly Diyi Pharmaceutical”
全部
13,511
临床试验
609
药物
1,793
机构
2,185
资讯
8,924
11个月前
Breast Cancer R&D Pipeline Expands to Over 300 Drugs with Novel PROTACs, ADCs, and CDK Inhibitors
5个月前
AP Biosciences and Tasly Amend Collaboration to Accelerate Global Development of Dual-Target Cancer Therapy AP505
去年
Hansoh Pharma's HS-20093 ADC Granted Breakthrough Therapy Designation for SCLC in China
去年
Recbio Initiates Phase III Trial of REC610 Shingles Vaccine in China
去年
Chinese Drugmaker Jiangsu Hengrui Becomes World's Top Clinical Trial Sponsor as China Transforms Global R&D Landscape
去年
Triastek Opens World's Largest 3D-Printed Pharmaceutical Facility in China, Targets 300 Million Tablets Annually
去年
Vcare Partners with Huadong Medicine for VC005 JAK1 Inhibitor Commercialization in China
7个月前
FDA Accepts First Quality Control Protocol for Mesenchymal Stromal Cells, Setting New Therapeutic Standard
6个月前
Merck KGaA Deepens China Investment with €170 Million Manufacturing Expansion and Drug Development Partnership
去年
Oral GLP-1R Obesity Drugs Race to Market as Novo Nordisk and Eli Lilly Lead Phase III Trials
第 1 页，共 893 页
上一页
下一页
